Skip to main content
. 2006 Apr 19;2006(2):CD005321. doi: 10.1002/14651858.CD005321.pub2

20. Clinical benefit table: Hyalgan versus corticosteroids and other IA therapy. Dic.

Study Time Treatment group Outcome No. improved No. of pts Risk (%) Risk Difference NNT
Leardini 1987 1‐4 wk T: Hyalgan Number of joints with moderate/severe pain under load 8 20 40 0  
    C: MPA   8 20 40    
Leardini 1991 1‐4 wk T: Hyalgan Number of patients with moderate/severe pain under load 14 20 70 25 4
    C: MPA   19 20 95    
Pietrogrande 1991 1‐4 wk T: Hyalgan Number of patients with moderate/severe pain under load 21 45 47 7 14.3
    C: MPA   18 45 40    
Leardini 1987 5‐13 wk T: Hyalgan Number of joints with moderate/severe pain under load 6 20 30 5 20
    C: MPA   7 20 35    
Leardini 1991 5‐13 wk T: Hyalgan Number of patients with moderate/severe pain under load 13 20 65 35 2.9
    C: MPA   20 20 100    
Pietrogrande 1991 5‐13 wk T: Hyalgan Number of patients with moderate/severe pain under load 13 44 30 21 4.8
    C: MPA   23 45 51    
Leardini 1987 45‐52 wk T: Hyalgan Number of joints with moderate/severe pain under load 8 15 53 12 8.3
    C: MPA   11 17 65    
Leardini 1987 1‐4 wk T: Hyalgan Number of joints with moderate/severe walking pain 11 20 55 10 10
    C: MPA   9 20 45    
Leardini 1987 5‐13 wk T: Hyalgan Number of joints with moderate/severe walking pain 8 20 40 10 10
    C: MPA   10 20 50    
Leardini 1987 45‐52 wk T: Hyalgan Number of joints with moderate/severe walking pain 11 15 73 2 50
    C: MPA   12 17 71    
Leardini 1991 1‐4 wk T: Hyalgan Number of patients with at least moderate or greater night pain 1 20 5 15 6.7
    C: MPA   4 20 20    
Pietrogrande 1991 1‐4 wk T: Hyalgan Number of patients with at least moderate or greater night pain 5 45 11 9 11.1
    C: MPA   1 45 2    
Leardini 1991 5‐13 wk T: Hyalgan Number of patients with at least moderate or greater night pain 0 20 0 20 5
    C: MPA   4 20 20    
Pietrogrande 1991 5‐13 wk T: Hyalgan Number of patients with at least moderate or greater night pain 0 44 0    
    C: MPA   2 45 4 4 25
Leardini 1991 1‐4 wk T: Hyalgan Number of patients with moderate or greater rest pain 6 20 30 30 3.3
    C: MPA   12 20 60    
Pietrogrande 1991 1‐4 wk T: Hyalgan Number of patients with moderate or greater rest pain 7 45 16 0 0
    C: MPA   7 45 16    
Leardini 1991 5‐13 wk T: Hyalgan Number of patients with moderate or greater rest pain 6 20 30 45 2.2
    C: MPA   15 20 75    
Pietrogrande 1991 5‐13 wk T: Hyalgan Number of patients with moderate or greater rest pain 1 44 2 5 20
    C: MPA   3 45 7    
Frizziero 2002 1‐4 wk T: Hyalgan Patient global (number of patients very good/good) 21 46 46 ‐40 2.5
    C: MPA   32 37 86    
Leardini 1991 1‐4 wk T: Hyalgan Patient global (number of patients very good/good) 11 20 55 10 10
    C: MPA   9 20 45    
Pietrogrande 1991 1‐4 wk T: Hyalgan Patient global (number of patients very good/good) 32 45 71 24 4.2
    C:MPA   21 45 47    
Leardini 1991 5‐13 wk T: Hyalgan Patient global (number of patients very good/good) 10 20 50 15 6.7
    C: MPA   7 20 35    
Pietrogrande 1991 5‐13 wk T: Hyalgan Patient global (numbe of patients very good/good) 31 45 69 36 2.8
    C: MPA   15 45 33    
Frizziero 2002 14‐26 wk T: Hyalgan Patient global (number of patients very good/good) 30 38 79 4 25
    C: MPA   24 32 75    
Graf 1993 (other ia therapy) 14‐26 wk T: Hyalgan Patient global (number of patients symptom free/markedly improved) 25 33 76 30 3.3
    C: Mucopolysaccharide polysulfuric acid ester   11 24 46